DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS

Brief description of study

If you have been diagnosed with a rare cancer or a rare cancer of unknown primary origin, you may qualify for this study. The main goal of this study is to test the effects of the study drugs ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Clinical Study Identifier: s18-00026

ClinicalTrials.gov Identifier: NCT02834013

Principal Investigator: Janice Mehnert.

Other Investigators: Minerva A Utate, Jeffrey S. Weber, David R. Wise, Salman Rafi Punekar, Nancy Chan, Maya Dimitrova.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies